

GLAXOSMITHKLINE PLC  
Form 6-K  
March 20, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending March 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Issued: Thursday, March 19, 2009, London UK

**GlaxoSmithKline Announces Sale of Shares in Quest Diagnostics Inc.**

GlaxoSmithKline plc (the "Group") announces today that it has sold 5,749,157 shares of common stock, par value of \$0.01 per share (the "Shares"), of Quest Diagnostics Inc. ("Quest").

The sale of the Shares was achieved partly through market sales under Rule 144 of the U.S. Securities Act of 1933, and, partly through a sale directly to Quest. Details of these transactions are provided below.

During the period 17<sup>th</sup> March to 19<sup>th</sup> March 2009, 1,237,500 Quest shares were sold in the market, as follows:

<b>Date</b>	<b>Number of Shares</b>	<b>Aggregate Price</b>	<b>Average Price</b>
17 <sup>th</sup> March 2009	500,000	\$22,749,150	\$45.50
18 <sup>th</sup> March 2009	500,000	\$22,852,050	\$45.70
19 <sup>th</sup> March 2009	237,500	\$10,541,960	\$44.39
Total	1,237,500	\$56,143,160	\$45.37

In addition to the market sales detailed above, on 19<sup>th</sup> March 2009, 4,511,657 Quest shares were sold back to Quest for \$44.33 per share, for an aggregate price of approximately \$200 million.

The Shares were sold as part of a gradual reduction in the Group's holding and to take advantage of Quest's recently expanded share repurchase programme. The Group originally acquired the Shares following the sale of the Group's clinical laboratories business to Quest in 1999.

Following the sale of the Shares, the Group holds 30,755,151 shares of common stock in Quest, being approximately 16.5% of the issued share capital of Quest, with a market value of approximately \$1.36 billion.

**S M Bicknell**  
**Company Secretary**

19 March 2009

**GlaxoSmithKline** – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit [www.gsk.com](http://www.gsk.com)

**Enquiries:**

UK Media enquiries:	Philip Thomson	(020) 8047 5502
	David Outhwaite	(020) 8047 5502
	Stephen Rea	(020) 8047 5502
US Media enquiries:	Nancy Pekarek	( 919 ) 483 2839
	Mary Anne Rhyne	(919) 483 2839
	Kevin Colgan	(919) 483 2839
	Sarah Alspach	(215) 751 7709
European Analyst/Investor enquiries:	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543
	Gary Davies	(020) 8047 5503
US Analyst/ Investor enquiries:	Tom Curry	(215) 751 5419
	Jen Hill	(215) 751 7002

**Cautionary statement regarding forward-looking statements**

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2008.

**Registered in England & Wales:**

No. 3888792

**Registered Office:**

980 Great West Road  
Brentford, Middlesex

TW8 9GS

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: March 20, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc